Pegadricase

Drug Profile

Pegadricase

Alternative Names: Pegsitacase; Pegsiticase; SEL 037; SSS11; Uricase-PEG 20

Latest Information Update: 25 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phoenix Pharmacologics
  • Developer 3SBio; Selecta Biosciences
  • Class Enzymes; Oxidoreductases; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Urate oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperuricaemia; Tumour lysis syndrome; Gout; Lesch-Nyhan syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout
  • Phase I/II Tumour lysis syndrome

Most Recent Events

  • 01 Oct 2016 Phase-II clinical trials in Gout in USA (IV) (NCT02959918)
  • 01 Jul 2016 Selecta Biosciences completes a phase-I clinical trial in Gout in USA (IM) (NCT02464605)
  • 18 Jun 2014 Pegadricase licensed to Selecta Biosciences in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top